Skip to main content

Table 3 Significantly different values in NK cell subsets in controls (Ctrl) and non-recurrent SCCHN patients

From: Comparison of the composition of lymphocyte subpopulations in non-relapse and relapse patients with squamous cell carcinoma of the head and neck before, during radiochemotherapy and in the follow-up period: a multicenter prospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)

% Ctrl t0 t1 t2 t3
CD56bright/CD16- NK cells 1.83 ± 1.14 2.48 ± 1.94 1.78 ± 1.65* 2.11 ± 1.55 2.25 ± 1.62
CD56bright/CD16+ NK cells 2.52 ± 1.34 4.72 ± 3.98* 3.72 ± 3.32 3.08 ± 2.15 4.09 ± 2.68
CD56dim/CD16 NK cells 2.8 ± 1.8 3.98 ± 2.82 4.42 ± 3.53 2.32 ± 1.33 7.5 ± 8.53
CD56dim/CD16+
NK cells
87.27 ± 5.97 83.10 ± 10.29 84.93 ± 10.49 89.3 ± 5.46* 82.8 ± 12.27
CD56/CD16+
NK cells
0 ± 0 0.01 ± 0.02 0.14 ± 0.27 0.05 ± 0.09 0.09 ± 0.16
  1. The significance is between the two underlined values. E.g. significance in CD56bright/CD16- NK cells between t0 and t1 is *p<=0.05
  2. Composition of NK cell subsets (CD56/CD16) in % (mean value ± standard deviation) in healthy controls (Ctrl, n = 22) and non-recurrent patients (n = 23) before (t0), after application of 20–30 Gy (t1), 3 months (t2) and 6 months (t3) after RCT. Significantly different values (t0 vs. t1; Ctrl vs. t0; t0 vs. t2) are indicated in bold with an asterisk (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001)